🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT05335083
Starting soon Not applicable

CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects

NCT05335083 · tracked via the Priya Life Science Australia tracker
Phase
Not applicable
Started
2025-07-01
Last updated
2025-04-01

Condition(s) studied

Obstructive Sleep ApneaPre-diabetes

Investigational drug(s) / intervention(s)

CPAP

CPAP: A positive CPAP intervention

Study summary

The purpose of the current study is to investigate whether alleviation of OSA by CPAP positively impacts glucose metabolism in non-diabetic patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Community dwelling adult males and females aged 18-65 years 2. Polysomnography confirmed moderate to severe OSA with apnea hypopnea index (AHI) ≥15/hr within the past 60 months 3. Able to give written informed consent 4. Proficient in English 6\. Diagnosed non-diabetic as defined by the American Diabetes Association as any of the following recent (\<3 months) findings: 1. Fasting glucose with a BGL \<7.0 mmol/L 2. Glucose tolerance with a 2-hour BGL of \< 11.1 mmol/L after a formal 75g Oral Glucose Tolerance Test (OGTT) 3. HbA1C of ≤ 6.5% 7. Possession or regular access to a mobile telephone with capability to download and run the Withings Sleep Anlayser App. Exclusion Criteria: 1. Clinically significant co-morbidity (e.g. myocardial infarction, congestive heart failure, stroke, arrythmia, chronic kidney or liver disease, epilepsy, head injury) 2. Severe mental health disorders (e.g. current major depressive disorder, schizophrenia, bipolar disorder) that in the opinion of the investigator is not adequately treated or will significantly affect their participation in the study. 3. Regular (\>2 times per month) use of sleep-affecting medication (e.g. benzodiazepines, opioids, antidepressants) 4. Regular night shift work or travel overseas within the last 2 weeks 5. Sleep physician has advised against CPAP withdrawal 6. Pregnancy 7. Active smoking or routine alcohol use (more than 2 standard drinks a day) or excessive caffeine intake (\>300 mg a day) or recent (in the past month) use of illicit drugs 8. Current or previous diagnosis of diabetes mellitus (previous gestational diabetes mellitus not excluded) 9. Current or recent (\<3 months) use of hypoglycaemic agents 10. Undergoing a weight loss programme 11. Contraindications for use of the FreeStyle Libre Pro Sensor. E.g. Known hypersensitivity to skin adhesives such as those used to attach the sensor to the arm.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Royal Prince Alfred Hospital Camperdown New South Wales
Woolcock Institute of Medical Research Macquarie Park New South Wales

More Woolcock Institute of Medical Research trials in Australia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05335083 on ClinicalTrials.gov ↗ ← All trials in Australia